Literature DB >> 28275485

Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease.

Hideaki Yamakawa1, Eri Hagiwara2, Hideya Kitamura1, Yumie Yamanaka1, Satoshi Ikeda2, Akimasa Sekine2, Tomohisa Baba2, Koji Okudela3, Tae Iwasawa4, Tamiko Takemura5, Kazuyoshi Kuwano6, Takashi Ogura2.   

Abstract

BACKGROUND: Interstitial lung disease (ILD) is frequent complication of systemic sclerosis (SSc) and mixed connective tissue disease (MCTD). The disease is heterogeneous, and its outcome is unpredictable. Some patients have severe and progressive deterioration of ILD, which is the leading cause of mortality. We aimed to determine whether serum levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) correlate with SSc/MCTD-associated ILD activity.
METHODS: We retrospectively analyzed the medical records of 40 patients with SSc/MCTD-associated ILD: 29 patients with SSc and 11 patients with MCTD. Measurement of serum KL-6 and SP-D levels, pulmonary function tests, and high-resolution computed tomography (HRCT) performed in parallel were reviewed.
RESULTS: Serum KL-6 correlated positively with diffusing capacity of the lung for carbon monoxide (DLCO) (% predicted) and disease extent on HRCT, and the changes in serum levels of KL-6 were significantly related to the changes in forced vital capacity (FVC) in SSc/MCTD-associated ILD. On the other hand, multivariate logistic regression analyses with calculation of the area under the curve of the receiver-operating characteristic curve suggested that a higher serum level of SP-D was a significant predictor of FVC decline in SSc/MCTD-associated ILD.
CONCLUSIONS: Our study suggests that serum KL-6 can be a useful monitoring tool of SSc/MCTD-associated ILD activity. In contrast, serum SP-D may be a significant predictor of potential FVC decline in the short term.

Entities:  

Keywords:  Systemic sclerosis (SSc); biomarker; interstitial lung disease (ILD); mixed connective tissue disease (MCTD)

Year:  2017        PMID: 28275485      PMCID: PMC5334095          DOI: 10.21037/jtd.2017.02.48

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  33 in total

1.  Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.

Authors:  K Yamane; H Ihn; M Kubo; N Yazawa; K Kikuchi; Y Soma; K Tamaki
Journal:  J Rheumatol       Date:  2000-04       Impact factor: 4.666

2.  Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study.

Authors:  Minoru Hasegawa; Yoshihide Asano; Hirahito Endo; Manabu Fujimoto; Daisuke Goto; Hironobu Ihn; Katsumi Inoue; Osamu Ishikawa; Yasushi Kawaguchi; Masataka Kuwana; Yoshinao Muro; Fumihide Ogawa; Tetsuo Sasaki; Hiroki Takahashi; Sumiaki Tanaka; Kazuhiko Takehara; Shinichi Sato
Journal:  Rheumatology (Oxford)       Date:  2011-11-09       Impact factor: 7.580

3.  "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity.

Authors:  Susanna Cappelli; Silvia Bellando Randone; Dušanka Martinović; Maria-Magdalena Tamas; Katarina Pasalić; Yannick Allanore; Marta Mosca; Rosaria Talarico; Daniela Opris; Csaba G Kiss; Anne-Kathrin Tausche; Silvia Cardarelli; Valeria Riccieri; Olga Koneva; Giovanna Cuomo; Mike Oliver Becker; Alberto Sulli; Serena Guiducci; Mislav Radić; Stefano Bombardieri; Martin Aringer; Franco Cozzi; Guido Valesini; Lidia Ananyeva; Gabriele Valentini; Gabriela Riemekasten; Maurizio Cutolo; Ruxandra Ionescu; László Czirják; Nemanja Damjanov; Simona Rednic; Marco Matucci Cerinic
Journal:  Semin Arthritis Rheum       Date:  2011-09-29       Impact factor: 5.532

4.  Comparison of pulmonary CT findings and serum KL-6 levels in patients with cryptogenic organizing pneumonia.

Authors:  F Okada; Y Ando; K Honda; S Tanoue; S Matsumoto; H Mori
Journal:  Br J Radiol       Date:  2008-12-08       Impact factor: 3.039

5.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

Review 6.  Does mixed connective tissue disease exist? Yes.

Authors:  Martin Aringer; Günter Steiner; Josef S Smolen
Journal:  Rheum Dis Clin North Am       Date:  2005-08       Impact factor: 2.670

Review 7.  Mixed connective tissue disease.

Authors:  Ragnar Gunnarsson; Siri Opsahl Hetlevik; Vibke Lilleby; Øyvind Molberg
Journal:  Best Pract Res Clin Rheumatol       Date:  2016-04-12       Impact factor: 4.098

8.  Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.

Authors:  Y Asano; H Ihn; K Yamane; N Yazawa; M Kubo; M Fujimoto; K Tamaki
Journal:  Arthritis Rheum       Date:  2001-06

9.  Mixed connective tissue disease: a subsequent evaluation of the original 25 patients.

Authors:  S H Nimelstein; S Brody; D McShane; H R Holman
Journal:  Medicine (Baltimore)       Date:  1980-07       Impact factor: 1.889

10.  Multicenter study of quantitative computed tomography analysis using a computer-aided three-dimensional system in patients with idiopathic pulmonary fibrosis.

Authors:  Tae Iwasawa; Tetsu Kanauchi; Toshiko Hoshi; Takashi Ogura; Tomohisa Baba; Toshiyuki Gotoh; Mari S Oba
Journal:  Jpn J Radiol       Date:  2015-11-06       Impact factor: 2.374

View more
  16 in total

1.  Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review.

Authors:  Yukai Wang; Shaoqi Chen; Zhangzhang Lin; Jianqun Lin; Xuezhen Xie; Qisheng Lin; Guangzhou Du; Xiufeng Huang; Marco Matucci-Cerinic; Daniel E Furst
Journal:  Clin Rheumatol       Date:  2019-02-11       Impact factor: 2.980

Review 2.  Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review.

Authors:  Anna-Maria Hoffmann-Vold; Toby M Maher; Edward E Philpot; Ali Ashrafzadeh; Oliver Distler
Journal:  ERJ Open Res       Date:  2021-02-22

3.  Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.

Authors:  Yun Peng; Suhan Zhang; Yi Zhao; Yi Liu; Bing Yan
Journal:  Clin Rheumatol       Date:  2017-08-25       Impact factor: 2.980

Review 4.  Assessment of disease outcome measures in systemic sclerosis.

Authors:  Robert Lafyatis; Eleanor Valenzi
Journal:  Nat Rev Rheumatol       Date:  2022-07-20       Impact factor: 32.286

5.  Circulating biomarkers of systemic sclerosis - interstitial lung disease.

Authors:  Anna-Maria Hoffmann-Vold; Håvard Fretheim; Chantal Meier; Britta Maurer
Journal:  J Scleroderma Relat Disord       Date:  2020-01-06

6.  Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.

Authors:  Changjiang Xue; Na Wu; Xue Li; Meihua Qiu; Xuqin Du; Qiao Ye
Journal:  BMC Pulm Med       Date:  2017-11-17       Impact factor: 3.317

Review 7.  Predictors of progression in systemic sclerosis patients with interstitial lung disease.

Authors:  Oliver Distler; Shervin Assassi; Vincent Cottin; Maurizio Cutolo; Sonye K Danoff; Christopher P Denton; Jörg H W Distler; Anna-Maria Hoffmann-Vold; Sindhu R Johnson; Ulf Müller Ladner; Vanessa Smith; Elizabeth R Volkmann; Toby M Maher
Journal:  Eur Respir J       Date:  2020-05-14       Impact factor: 16.671

8.  Vitamin D levels are prognostic factors for connective tissue disease associated interstitial lung disease (CTD-ILD).

Authors:  Yujuan Gao; Qi Zhao; Xiaohua Qiu; Yi Zhuang; Min Yu; Jinghong Dai; Hourong Cai; Xin Yan
Journal:  Aging (Albany NY)       Date:  2020-03-12       Impact factor: 5.682

9.  Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.

Authors:  Dinesh Khanna; Donald P Tashkin; Christopher P Denton; Elisabetta A Renzoni; Sujal R Desai; John Varga
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

10.  Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.

Authors:  Xiao-Yu Cao; Sha-Sha Hu; Dong Xu; Meng-Tao Li; Qian Wang; Yong Hou; Xiao-Feng Zeng
Journal:  Int J Rheum Dis       Date:  2018-12-28       Impact factor: 2.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.